Multifunctional roles of enolase in Alzheimer’s disease brain: beyond altered glucose metabolism
Open Access
- 16 October 2009
- journal article
- review article
- Published by Wiley in Journal of Neurochemistry
- Vol. 111 (4), 915-933
- https://doi.org/10.1111/j.1471-4159.2009.06397.x
Abstract
Enolase enzymes are abundantly expressed, cytosolic carbon‐oxygen lyases known for their role in glucose metabolism. Recently, enolase has been shown to possess a variety of different regulatory functions, beyond glycolysis and gluconeogenesis, associated with hypoxia, ischemia, and Alzheimer’s disease (AD). AD is an age‐associated neurodegenerative disorder characterized pathologically by elevated oxidative stress and subsequent damage to proteins, lipids, and nucleic acids, appearance of neurofibrillary tangles and senile plaques, and loss of synapse and neuronal cells. It is unclear if development of a hypometabolic environment is a consequence of or contributes to AD pathology, as there is not only a significant decline in brain glucose levels in AD, but also there is an increase in proteomics identified oxidatively modified glycolytic enzymes that are rendered inactive, including enolase. Previously, our laboratory identified α‐enolase as one the most frequently up‐regulated and oxidatively modified proteins in amnestic mild cognitive impairment (MCI), early‐onset AD, and AD. However, the glycolytic conversion of 2‐phosphoglycerate to phosphoenolpyruvate catalyzed by enolase does not directly produce ATP or NADH; therefore it is surprising that, among all glycolytic enzymes, α‐enolase was one of only two glycolytic enzymes consistently up‐regulated from MCI to AD. These findings suggest enolase is involved with more than glucose metabolism in AD brain, but may possess other functions, normally necessary to preserve brain function. This review examines potential altered function(s) of brain enolase in MCI, early‐onset AD, and AD, alterations that may contribute to the biochemical, pathological, clinical characteristics, and progression of this dementing disorder.Keywords
This publication has 168 references indexed in Scilit:
- Redox proteomics identification of 4‐hydroxynonenal‐modified brain proteins in Alzheimer's disease: Role of lipid peroxidation in Alzheimer's disease pathogenesisProteomics – Clinical Applications, 2009
- Loss of phospholipid asymmetry and elevated brain apoptotic protein levels in subjects with amnestic mild cognitive impairment and Alzheimer diseaseNeurobiology of Disease, 2008
- Roles of amyloid β-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairmentFree Radical Biology & Medicine, 2007
- 6-Hydroxydopamine induces mitochondrial ERK activationFree Radical Biology & Medicine, 2007
- Plasminogen/plasmin regulates α-enolase expression through the MEK/ERK pathwayBiochemical and Biophysical Research Communications, 2005
- Plasminogen/plasmin regulates c-fos and egr-1 expression via the MEK/ERK pathwayBiochemical and Biophysical Research Communications, 2005
- Tissue-Type Plasminogen Activator Is a Multiligand Cross-β Structure ReceptorCurrent Biology, 2002
- LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted β-amyloid precursor protein and mediates its degradationCell, 1995
- Synthetic Peptide Corresponding to 30 Amino Acids of the C-Terminal of Neuron-Specific Enolase Promotes Survival of Neocortical Neurons in CultureBiochemical and Biophysical Research Communications, 1994
- The effect of ferricyanide with iodoacetate in calcium-free solution on passive cation permeability in human red blood cells: comparison with the Gardos-effect and with the influence of PCMBS on passive cation permeabilityBiochimica et Biophysica Acta (BBA) - Biomembranes, 1989